Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JPMA Suspends MSD from Membership for Violations of Promotion Code
June 27, 2011
- Novoseven Approved for Glanzmann Thrombasthenia
June 27, 2011
- Zeria's Z-338 Effective for 3 Major Meal-related Symptoms
June 27, 2011
- Doctors Appreciate Companies That Supply Information in Emergencies
June 27, 2011
- HeW CO-OP JAPAN Aims to Jointly Purchase ¥3 Bil. Worth of Drugs in FY2011
June 27, 2011
- Bayer HealthCare Applies for VEGF Trap-Eye in Europe
June 27, 2011
- Radioactive Anticancer Agent Significantly Extends OS in PIII Study: Bayer HealthCare
June 27, 2011
- Fuso Applies for Surgical Hemostatic Product
June 20, 2011
- OncoTherapy Closes Patient Enrollment for PII Trial of OTS102 for Biliary Tract Cancer
June 20, 2011
- CellSeed Applies for Epithelial Cell Sheet for Corneal Regeneration
June 20, 2011
- FDA Not to Require PIII Data on Intranasal Granisetron: SNBL
June 20, 2011
- Daiichi Sankyo: Novel AD Treatment Memary Tablets
June 20, 2011
- Pfizer Japan Files Public Knowledge-based Application for Diflucan
June 20, 2011
- US CRO to Provide Financial Support to Codevelopment Partner of MediBIC
June 20, 2011
- Amgen to Focus on 4 Fields Including Cancer Taking Advantage of Its Strength in Biotech
June 20, 2011
- Novartis Files Public Knowledge-based Applications for Add'l Indications for 3 More Products
June 20, 2011
- Takeda Presents PI Data on MLN4924 at ASCO
June 20, 2011
- Bayer to Strengthen Its PV Division
June 20, 2011
- FDA Approves pNET as Additional Indication for Sutent: Pfizer
June 20, 2011
- Axitinib Increases PFS Compared to Sorafenib in Previously Treated RCC Patients: ASCO
June 20, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…